Key result
Global development assistance for CVD in LMICs is increasing by ~$37 million annually.
Why the study?
Cardiovascular disease is the leading cause of premature mortality in LMICs, but the scale, distribution, and trajectory of international development assistance for CVD have not been systematically characterized.
Observational (n=4,507,692)
Yes
Effect estimate: Average annual percent change US$37.03 million (95% CI US$15.45-67.15 million)
p-value: p=< 0.001
Global development assistance for cardiovascular disease in LMICs between 2007 and 2023 remained exceedingly low at 0.008% of total aid, highlighting an urgent need for increased funding.
Highlights expanding cardiovascular research resources; leaves open impact on innovation, trial output, and clinical outcomes.
Background: Cardiovascular disease (CVD) is the leading cause of premature mortality in low- and middle-income countries (LMICs). However, the scale, distribution and trajectory of international development assistance for CVD have not been systematically characterized. Understanding these patterns is essential for informing targeted policy interventions and optimizing resource allocation. Hypothesis: Development assistance for CVD is limited, concentrated among a few donors and recipients, and marked by temporal volatility. Methods: We examined development assistance projects reported to the Organisation for Economic Co-operation and Development (OECD) Creditor Reporting System between 2007 and 2023. We identified CVD-related projects using a keyword-based search strategy, translated across 21 languages. We analyzed funding trends across 34 donors and 65 recipients, including countries and regions. Joinpoint regression was applied to identify statistically significant changes in disbursements over time. Results: Of the 4,507,692 projects analyzed, 815 were identified as CVD-related. These received US$434.98 million in disbursements, representing 0.008% of all international development assistance funding. The three largest donors, including the United Kingdom (US$71.62 million), the Wellcome Trust (US$70.17 million), and the United States (US$48.16 million), accounted for 43.7% of total CVD-related aid. The three largest recipient countries were Uganda (US$50.71 million), Uzbekistan (US$41.77 million), and Kenya (US$30.85 million). Funding declined significantly during the COVID-19 pandemic to US$9.99 million in 2019 and US$9.36 million in 2020, then rebounded to US$63.99 million in 2023. Joinpoint analysis identified four significant transition points (2011, 2014, 2017, 2020), with an average annual percent change of US$37.03 million (95% CI: US$15.45-67.15 million; p < 0.001). Conclusions: Between 2007 and 2023, CVD-related development assistance to LMICs remained exceedingly low, fragmented, and donor-dominated. These findings highlight the urgent need for global health donors to elevate CVD within funding priorities, expand support to LMICs, and commit to equitable financing strategies.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2026) conducted an observational in Cardiovascular disease (n=4,507,692). Global Development Assistance was evaluated on Changes in disbursements over time (Average annual percent change US$37.03 million, 95% CI US$15.45-67.15 million, p=< 0.001). Global development assistance for cardiovascular disease in LMICs between 2007 and 2023 totaled US$434.98 million (0.008% of total aid), with an average annual percent change of US$37.03 million (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: